Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

9.3K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
9.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.2K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.2K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
Antibody Actions01:26

Antibody Actions

2.2K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

867
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
867

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab.

Frontiers in medicine·2026
Same author

Update on therapeutic approaches in ANCA-associated vasculitis.

EULAR rheumatology open·2026
Same author

Long-term risk of malignancies in ANCA-associated vasculitis.

EULAR rheumatology open·2026
Same author

Radiological staging clinical decision support model for rectal cancer lymph node metastasis detection on MRI.

BMC cancer·2026
Same author

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis.

Clinical pharmacology and therapeutics·2026
Same author

Indocyanine green fluorescence angiography for anastomotic perfusion assessment in colorectal surgery: a systematic review with meta-analysis, meta-regression, and trial sequential analyses.

The lancet. Gastroenterology & hepatology·2026
Same journal

Supporting patients and family members facing treatment choices in chronic kidney disease: What do professionals think of the decision aids used? - Professionals’ views on treatment decision support tools

Nephrologie & therapeutique·2026
Same journal

From Turing to ChatGPT: The origins and transformations of medical artificial intelligence

Nephrologie & therapeutique·2026
Same journal

Analysis of the predictive value of serum Cys-C and IL-6 levels for acute kidney injury in patients with acute respiratory distress syndrome.

Nephrologie & therapeutique·2026
Same journal

Navigating pain in chronic kidney disease: Overcoming inertia!

Nephrologie & therapeutique·2026
Same journal

Kidney health for all: caring for people, protecting the planet1.

Nephrologie & therapeutique·2026
Same journal

When the heart breaks, the kidneys follow: A case of Takotsubo syndrome

Nephrologie & therapeutique·2026
See all related articles

Related Experiment Video

Updated: Jan 5, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

31.1K

Complement inhibition in ANCA vasculitis.

David Jayne1

  • 1Department of medicine, University of Cambridge, Addenbrookes Hospital, Box 115, Level 5, Cambridge CB2 2OQ, UK.

Nephrologie & Therapeutique
|October 22, 2019
PubMed
Summary
This summary is machine-generated.

The alternative complement pathway is key in ANCA vasculitis. C5a inhibitors like avacopan show promise for treating this condition, potentially reducing reliance on steroids and improving remission quality.

Keywords:
ANCAC5aClinical trialComplementTherapyVasculitis

More Related Videos

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.5K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

Related Experiment Videos

Last Updated: Jan 5, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

31.1K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.5K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

Area of Science:

  • Immunology
  • Rheumatology
  • Nephrology

Background:

  • The alternative complement pathway plays a significant role in ANCA vasculitis pathogenesis.
  • Current ANCA vasculitis therapies have limited efficacy, toxicity, and often result in relapsing disease courses.
  • There is a critical need for improved therapeutic strategies.

Purpose of the Study:

  • To explore the potential of C5a inhibition in managing ANCA vasculitis.
  • To evaluate the efficacy and safety of C5a inhibitors as novel therapeutic agents.
  • To assess the possibility of replacing corticosteroids and preventing disease relapse.

Main Methods:

  • Review of current understanding of ANCA vasculitis pathogenesis.
  • Analysis of clinical development of C5a inhibitors, including avacopan (C5a receptor inhibitor) and IFX-1 (anti-C5a monoclonal antibody).
  • Examination of Phase II trial data for avacopan regarding efficacy, safety, and steroid-sparing effects.

Main Results:

  • Avacopan demonstrated efficacy, safety, and steroid-sparing capabilities in two Phase II trials for ANCA vasculitis.
  • IFX-1 is progressing into Phase II development for ANCA vasculitis.
  • C5a inhibition targets key mechanisms of neutrophil activation and migration in ANCA vasculitis.

Conclusions:

  • C5a inhibition is a promising therapeutic strategy for ANCA vasculitis, offering potential for improved remission quality and steroid replacement.
  • Further studies are required to confirm the safety profile, particularly infective risks, and to explore the role of C5a inhibitors in relapse prevention.